Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response-Reference-Cited by-同舟云学术

Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response

Published:2011-10-20 Issue:4 Volume:155 Page:457-467
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Chanan-Khan Asher A.,Chitta Kasyapa,Ersing Noreen,Paulus Aneel,Masood Aisha,Sher Taimur,Swaika Abhisek,Wallace Paul K.,Mashtare Terry L.,Wilding Greg,Lee Kelvin,Czuczman Myron S.,Borrello Ivan,Bangia Naveen

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2011.08882.x/fullpdf

Reference45 articles.

1. Lenalidomide and thalidomide: mechanisms of action - similarities and differences;Anderson;Seminars in Hematology,2005

2. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia;Andritsos;Journal of Clinical Oncology,2008

3. Anti-tumor reactivity of human lymphokine activated killer (LAK) cells against fresh and cultured preparations of renal cell cancer;Belldegrun;Journal of Urology,1988

4. Malignant chronic lymphocytic leukemia B cells elaborate soluble factors that down-regulate T cell and NK function;Burton;American Journal of Hematology,1989

5. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211;Byrd;Leukemia,2003

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maintenance low-dose fixed duration lenalidomide and rituximab following bendamustine and rituximab induction in previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma;Leukemia & Lymphoma;2024-06-10

2. Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis;Clinical Lymphoma Myeloma and Leukemia;2024-06

3. Lenalidomide Treatment of Isolated Central Nervous System Relapse in Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy;Acta Haematologica;2024-02-15

4. Assessment of Response to Immunotherapy in Patients with Hodgkin Lymphoma: Towards Quantifying Changes in Tumor Burden Using FDG-PET/CT;Journal of Clinical Medicine;2023-05-16

5. Emerging Therapies in CLL in the Era of Precision Medicine;Cancers;2023-03-03